natgillin/translations-raw huggingface dataset:
• Patients should be monitored for antibodies against human hepatitis B immunoglobulin regularly.
• Pri bolnikih je treba redno meriti protitelesa proti človeškemu imunoglobulinu proti hepatitisu B.
IgG and IgG-complexes are broken down in the reticuloendothelial system.
Razpolovna doba se lahko razlikuje od bolnika IgG in komplekse IgG razkraja retikuloendotelni sistem.
This also applies to unknown or emerging viruses and
To velja tudi za neznane ali porajajoče se viruse in druge povzročitelje bolezni.
The table below provides a recommended dose.
Priporočeni odmerek je naveden v spodnji preglednici.
Consideration should also be given to other official guidance on the appropriate use of human hepatitis B immunoglobulin for imtramuscular use.
Upoštevajte tudi druga uradna priporočila o primerni uporabi človeškega imunoglobulina proti hepatitisu B za intramuskularno uporabo.
Ensure that ImmunoGam is not administered into a blood vessel, because of the risk of shock.
Zdravila ImmunoGam ne smete injicirati v žilo zaradi nevarnosti šoka.
These undesirable effects were reported within the first 7 days after receiving ImmunoGam: nausea, fatigue, induration (swelling and firmness) at the injection site, feeling unwell, pain, fever, joint pain, back pain, muscle pain, headache and dizziness.
V prvih sedmih dneh po uporabi zdravila ImmunoGam so bili prijavljeni naslednji občasni neželeni učinki: slabost, utrujenost, zatrdlina (trda oteklina) na mestu injiciranja, slabo počutje, bolečine, zvišana telesna temperatura, bolečine v sklepih, bolečine v hrbtu, bolečine v mišicah, glavobol in omotica.
Also transmission of antibodies to blood group antigens may interfere with some blood tests for red cell allo-antibodies (e.g. Coombs' test).
Prenos protiteles proti antigenom krvnih skupin lahko tudi moti določene krvne preiskave za aloprotitelesa proti eritrocitom (npr. Coombsov test).
At least 500 IU depending on the intensity of exposure, as soon as possible after exposure, and preferably within 24 - 72 hours every 2 months until seroconversion following
Pogostnost uporabe odvisno od intenzivnosti izpostavitve, čim prej po izpostavitvi in po možnosti v 24-72 urah
The product information of the blood glucose testing systems, including that of the test strips, should be carefully reviewed to determine if the system is appropriate for use with maltose-containing parenteral products.
Natančno preglejte podatke o sistemu za merjenje glukoze v krvi ter o merilnih lističih, da preverite, ali je sistem primeren za uporabo s parenteralnimi zdravili, ki vsebuje maltozo.
You should NOT be given ImmunoGam - if you have previously developed an allergic reaction to human immunoglobulins, to other blood products or to any of the other ingredients of ImmunoGam.
Zdravila ImmunoGam NE smete prejeti - če ste kdaj imeli alergijsko reakcijo na človeške imunoglobuline, druge krvne pripravke ali katero koli sestavino zdravila ImmunoGam, - če imate pomanjkljivost IgA in ste imeli alergijsko reakcijo na zdravila, ki vsebujejo IgA.
- Immunoprophylaxis of hepatitis B in haemodialysed patients: 8-12 IU/kg with a maximum of 500 IU, every 2 months until seroconversion following vaccination.
- Imunoprofilaksa proti hepatitisu B pri bolnikih na hemodializi: 8-12 i.e./kg oz. največ 500 i.e., vsaka dva meseca do serokonverzije po cepljenju.
The frequency of possible side effects listed below is defined using the following convension: - very common (affects more than 1 user in 10) - common (affects 1 to 10 users in 100) - uncommon (affects 1 to 10 users in 1,000) - rare (affects 1 to 10 users in 10,000) - very rare (affects less than 1 user in 10,000) - not known (frequency cannot be estimated from the available data)
- zelo pogosti (pri več kot 1 osebi od 10 ljudi), - pogosti (pri 1 do 10 ljudeh od 100 ljudi), - občasni (pri 1 do 10 ljudeh od 1.000 ljudi), - redki (pri 1 do 10 ljudeh od 10.000 ljudi), - zelo redki (pri manj kot 1 osebi od 10.000 ljudi), - ni znano (pogostnosti ni mogoče oceniti iz razpoložljivih podatkov).
• Do not use ImmunoGam if the solution appears cloudy or has deposits.
• Ne uporabljajte zdravila ImmunoGam, če je raztopina motna ali ima usedlino.
When simultaneous vaccination is necessary, the immunoglobulin and the vaccine should be administered at two different sites.
Če je potrebno sočasno cepljenje, imunoglobulin in cepivo uporabite na dveh različnih predelih telesa.
Accordingly, when administering ImmunoGam or other parenteral maltose-containing products, the measurement of blood glucose must be done with a glucose-specific method.
Zaradi tega je treba po uporabi zdravila ImmunoGam ali drugega parenteralnega zdravila, ki vsebuje maltozo, glukozo v krvi meriti z metodo, ki je specifična za glukozo.
However, it should be noted that there are no clinical efficacy data to support administration by the subcutaneous route.
Vendar morate upoštevati, da ni podatkov o klinični učinkovitosti
In subjects who did not show an immune response (no measurable hepatitis B antibodies) after vaccination, and for whom continuous prevention is necessary, administration of 500 IU to adults and 8 IU/kg to children every 2 months can be considered; a minimum protective antibody titre is considered to be 10 mIU/ml.
Pri osebah, ki po cepljenju niso imele imunskega odziva (brez merljive količine protiteles proti virusu hepatitisa B), in pri osebah, pri katerih je obvezno stalno preprečevanje, upoštevajte odmerjanje 500 i.e. za odrasle in 8 i.e./kg za otroke na vsaka dva meseca; za najmanjši zaščitni titer protiteles se lahko šteje 10 mi.e./ml.
For intramuscular administration, ImmunoGam should be injected into the upper part of the shoulder (deltoid muscle), or into the right part of the thigh in the front (anteriolateral thigh) in newborn children.
Zdravilo ImmunoGam pri intramuskularni uporabi injiciramo v zgornji del rame (deltoidno mišico), pri novorojenčki pa v desni prednji del stegna (anterolateralni predel stegna).
One vial of 5 ml contains 1560 IU of anti-HBs.
Ena viala s 5 ml vsebuje 1560 i.e. protiteles proti HBs.
This may result in falsely elevated glucose readings and consequently in the inappropriate administration of insulin which may result in hypoglycemia.
To lahko povzroči lažno zvišane rezultate za glukozo in posledično neustrezno uporabo inzulina, kar lahko povzroči hipoglikemijo.
Please tell your doctor immediately if you experience any of the following symptoms after o hives, flushed skin or rash, swelling of a specific area such as the injection site or face o chest tightness, shortness of breath, wheezing o rapid increase in heart beat, sudden drop in blood pressure and/or shock These symptoms may be early signs of an allergic reaction.
Nemudoma obvestite zdravnika, če se pri vas po prejemu zdravila ImmunoGam pojavi katerikoli od o koprivnica, pordela koža ali izpuščaj, otekanje specifičnega področja, kot je mesto injiciranja o tesnoba v prsnem košu, zasoplost, sopenje, o nenadna pospešitev srčnega utripa, nenaden padec krvnega tlaka in/ali šok.
One vial of 1 ml contains 312 IU of anti-HBs.
Ena viala z 1 ml zdravila vsebuje 312 i.e. protiteles proti HBs.
Consideration should also be given to dose and dose schedules for human hepatitis B immunoglobulin for intramuscular use recommended in other official guidance.
Upoštevajte tudi odmerek in shemo odmerjanja človeškega imunoglobulina proti hepatitisu B za intramuskularno uporabo v drugih uradnih priporočilih.
This may result in falsely elevated glucose readings and consequently in the inappropriate administration of insulin, resulting in life-threatening hypoglycemia.
To lahko povzroči lažno zvišane rezultate za glukozo in posledično neprimerno uporabo inzulina, kar lahko povzroči življenje ogrožajočo hipoglikemijo.
Store in a refrigerator (2 ºC to 8ºC).
Shranjujte v hladilniku (od 2 °C do 8 °C).
Blood glucose testing: when administering ImmunoGam, the measurement of blood glucose must be done with a glucose-specific method.
Meritve glukoze v krvi: po uporabi zdravila ImmunoGam je treba glukozo v krvi meriti z metodo, ki je specifična za glukozo.
It is strongly recommended that every time ImmunoGam is administered to a patient, the name and batch number of the medicinal product are recorded in order to maintain a link between the patient and the batch
Zelo priporočljivo je, da pri vsaki uporabi zdravila ImmunoGam zabeležite ime in številko serije zdravila, da ohranite sledljivost med bolnikom in serijo zdravila.
Despite this, when medicinal products prepared from human blood or plasma are administered, the possibility of transmitting infective agents cannot be totally excluded.
Kljub temu pri uporabi zdravil, pripravljenih iz človeške krvi ali plazme, možnosti prenosa povzročiteljev nalezljivih bolezni ni možno popolnoma izključiti.
ImmunoGam is supplied in a Type 1 glass vial with a siliconized bromobutyl rubber stopper, aluminum seal and
Zdravilo ImmunoGam se dobavlja v viali iz stekla tipa I s silikoniziranim zamaškom iz bromobutilnega kavčuka, aluminijastim pečatom in potezno plastično zaporko (»flip-off«).
Related undesirable effects within 7 days of ImmunoGam administration, from clinical trials conducted using the intramuscular route of administration is tabulated below:
V spodnji preglednici so navedeni povezani neželeni učinki v sedmih dneh po intramuskularni uporabi zdravila ImmunoGam, ugotovljeni v kliničnih preskušanjih:
Immunoglobulin administration may interfere with the development of an immune response to live attenuated virus vaccines such as rubella, mumps, measles and varicella for a period of 3 months.
Uporaba imunoglobulina lahko v treh mesecih po uporabi moti razvoj imunskega odziva proti cepivom z živim, oslabljenim virusom, kot so cepiva proti rdečkam, mumpsu, ošpicam in noricam.
SPECIAL WARNING THAT THE MEDICINAL PRODUCT MUST BE STORED OUT OF THE
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN POGLEDA
ImmunoGam is a clear to slightly opalescent and colourless or pale yellow liquid.
Zdravilo ImmunoGam je bistra do rahlo motna in brezbarvna ali bledo rumena tekočina.
BEFORE YOU RECEIVE IMMUNOGAM
KAJ MORATE VEDETI, PREDEN BOSTE PREJELI ZDRAVILO IMMUNOGAM
• Immunoglobulins in general may cause adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia (joint pain), low blood pressure and moderate low back pain.
• Na splošno se pri uporabi imunoglobulinov lahko pojavijo neželene reakcije, kot so mrazenje, glavobol, zvišana telesna temperatura, bruhanje, alergijske reakcije, slabost, artralgija (bolečine v sklepih), nizek krvni tlak in zmerna bolečina v križu.
The first vaccine dose can be injected the same day as human hepatitis B immunoglobulin, however in different sites.
Prvi odmerek cepiva se lahko uporabi isti dan kot človeški imunoglobulin proti hepatitisu B, vendar na različnih predelih telesa.
Uncommon (≥1/1,000 to <1/100) Uncommon (≥1/1,000 to <1/100) Uncommon (≥1/1,000 to <1/100)
Občasni (≥1/1.000 do <1/100) Občasni (≥1/1.000 do <1/100)
Despite these measures, when medicines prepared from human blood or plasma are administered the possibility of passing on infection cannot be totally excluded.
Kljub tem postopkom pri uporabi zdravil, pripravljenih iz človeške krvi ali plazme, možnosti prenosa povzročiteljev nalezljivih bolezni ni možno popolnoma izključiti.
Passive transmission of antibodies to erythrocyte antigens, e.g. A, B, D may interfere with some serological tests for red cell allo-antibodies (e.g.Coombs' test).
A, B, D, lahko moti določene serološke preiskave za aloprotitelesa proti eritrocitom (npr. Coombsov test).
The measures taken may be of limited value against non-enveloped viruses such as HAV and parvovirus B19.
Postopki so manj učinkoviti proti virusom brez ovojnice, kot sta HAV in parvovirus B19.
Human hepatitis B immunoglobulin should be administrated three to four weeks after vaccination with such a live attenuated vaccine; in case administration of human hepatitis B immunoglobulin is essential within three to four weeks after vaccination, then revaccination should be performed three months after the administration of
V primeru človeškega imunoglobulina proti hepatitisu B je ključno počakati tri do štiri tedne po cepljenju, nato se opravi ponovno cepljenje tri mesece po uporabi človeškega imunoglobulina proti hepatitisu B.
If more ImmunoGam is used than recommended
Če se uporabi večji odmerek zdravila ImmunoGam, kot je dovoljeno Podatkov o prevelikem odmerjanju ni.
• When new information is received that may impact on the current Safety Specification,
Poleg tega je treba predložiti posodobljen načrt obvladovanja tveganja: • če se pridobijo novi podatki, ki lahko vplivajo na trenutne podatke o varnosti, načrt farmakovigilance ali
Detailed information on this medicinal product is available on the website of the European Medicines Agency
Podrobne informacije o zdravilu so objavljene na spletni strani Evropske agencije za zdravila http://www.ema.europa.eu
- In subjects who did not show an immune response (no measurable hepatitis B antibodies) after vaccination and for whom a continuous prevention is necessary due to the continuous risk of being infected with hepatitis B.
- pri bolnikih na hemodializi, dokler cepivo ne postane učinkovito, - pri novorojencih, rojenih prenašalkam virusa hepatitisa B, - pri osebah, ki po cepljenju ne kažejo imunskega odziva (brez merljive količine protiteles proti virusu hepatitisa B), in pri osebah, pri katerih je obvezno stalno preprečevanje zaradi stalnega tveganja okužbe z virusom hepatitisa B.
Each ml contains 312 IU Human hepatitis B immunoglobulin, corresponding to a protein content of 30-70 mg/ml of which 96% is Immunoglobulin G (IgG).
En mililiter vsebuje 312 i.e. človeškega imunoglobulina proti hepatitisu B, kar ustreza vsebnosti beljakovin 30-70 mg/mL, od česar je 96 % imunoglobulina G (IgG).
In case of intramuscular administration, some discomfort may occur occasionally at the site of injection such as local pain or tenderness.
Pri intramuskularni uporabi se lahko na mestu injiciranja občasno pojavita lokalna bolečina in občutljivost.
In general for immunoglobulin products, adverse reactions such as chills, headache, fever, vomiting, allergic reactions, nausea, arthralgia, low blood pressure and moderate low back pain may occur occasionally.
Na splošno se pri uporabi imunoglobulinskih zdravil občasno pojavijo neželene reakcije, kot so mrazenje, glavobol, zvišana telesna temperatura, bruhanje, alergijske reakcije, navzea, artralgija, nizek krvni tlak in
The hepatitis B immunoglobulin administration may need to be repeated until seroconversion following vaccination
uporabo imunoglobulina proti hepatitisu B je morda potrebno po cepljenju ponavljati do serokonverzije
This is because Some types of blood glucose testing systems falsely interpret the maltose contained in ImmunoGam as glucose.
Določene vrste sistemov za merjenje glukoze v krvi lahko prisotno maltozo v zdravilu ImmunoGam prikažejo kot glukozo.
The solution should be clear to slightly opalescent and colourless or pale yellow.
Raztopina mora biti bistra do rahlo motna in brezbarvna ali bledo rumena.
oC).
Navzea
The measures taken may be of limited value against non-enveloped viruses such as hepatitis A virus and parvovirus B19.
Postopki so manj učinkoviti proti virusom brez ovojnice, kot sta virus hepatitisa A in parvovirus B19.
The solution should be clear to slightly opalescent and colourless or pale yellow essentially free of foreign particles.
Raztopina mora biti bistra do rahlo motna in brezbarvna ali bledo rumena ter brez vidnih tujkov.
ImmunoGam should be administered via the intramuscular route.
Zdravilo ImmunoGam morate dajati intramuskularno.
Prevention of hepatitis B in the newborn, of a hepatitis B virus carrier-mother, at birth or
Preprečevanje hepatitisa B pri novorojencu, rojenemu prenašalki virusa hepatitisa B,
No adverse events were reported in the post marketing use of ImmunoGam for Immunoprophylaxis of
Izkušnje po pridobitvi dovoljenja za promet: V obdobju trženja zdravila ImmunoGam za indikacijo imunoprofilaksa proti hepatitisu B ni bilo prijavljenih
One vial contains 312 IU of anti-HBs in 1 ml One vial contains 1560 IU of anti-HBs in 5 ml
Ena viala vsebuje 1.560 i.e. protiteles proti HBs v 5 ml
If any uncertainty exists, the manufacturer of the testing system should be contacted to determine if the system is appropriate for use with
Če ste v dvomih, se obrnite na izdelovalca merilnega sistema, da preverite, ali je sistem primeren za uporabo s parenteralnimi zdravili, ki vsebuje maltozo.
ImmunoGam should be brought to room temperature (approximately 20°C to 25°C ) before use.
Pred uporabo zdravila ImmunoGam počakajte, da se zdravilo ogreje na sobno temperaturo (približno od 20 ºC do 25 ºC).
• Please inform your doctor if you are planning to receive a vaccine or have been recently vaccinated in the last three months.
• Obvestite svojega zdravnika, če načrtujete cepljenje ali ste bili cepljeni v zadnjih treh mesecih, saj lahko zdravilo ImmunoGam moti odziv na nekatera oslabljena cepiva, kot so cepiva proti ošpicam, rdečkam,
- Prevention of hepatitis B in the newborn, of a hepatitis B virus carrier-mother, at birth or as soon as
- Preprečevanje hepatitisa B pri novorojencu, rojenemu prenašalki virusa hepatitisa B, ob rojstvu ali čim 30-100 i.e./kg.
ImmunoGam should be brought to room temperature (approximately 20°C to 25°C) before use
Pred uporabo zdravila ImmunoGam počakajte, da se zdravilo segreje na sobno temperaturo (približno od 20 ºC do 25 ºC)
Depending on the nature and severity of the allergic reaction, your doctor may give you an additional treatment or your doctor may decide to stop the
Vaš zdravnik vas bo morda dodatno zdravil ali nemudoma prekinil injiciranje, odvisno od narave in resnosti alergijske reakcije.
ImmunoGam 312 IU/ml solution for injection
ImmunoGam, 312 i.e./ml, raztopina za injiciranje Človeški imunoglobulin proti hepatitisu B
The hepatitis B immunoglobulin administration may need to be repeated until
Uporabo imunoglobulina proti hepatitisu B je morda po cepljenju treba ponavljati
Human hepatitis B immunoglobulin for intramuscular use is bioavailable in the recipient's circulation after a delay of 2 - 3 days.
Človeški imunoglobulin proti hepatitisu B za intramuskularno uporabo je biološko uporaben v krvnem obtoku
There is reassuring clinical experience regarding the lack of hepatitis A or parvovirus B19 transmission with immunoglobulins and it is also assumed that the antibody content makes an important contribution to
Klinične izkušnje podpirajo podmeno, da se virus hepatitisa A oz. parvovirusa B19 z imunoglobulini ne prenašata.
Live attenuated virus vaccines
Bolezni prebavil
ImmunoGam contains increased levels of human hepatitis B immunoglobulins mainly immunoglobulin G (IgG) and is obtained from blood plasma of screened donors from
Zdravilo ImmunoGam vsebuje povečane količine človeških imunoglobulinov proti hepatitisu B, zlasti imunoglobulin G (IgG).
ImmunoGam comes in a 1 ml or 5 ml vial containing 30-70 mg/ml of human plasma protein of which 96% (312 IU/ml) is Immunoglobulin G (IgG).
- Zdravilna učinkovina je človeški imunoglobulin proti hepatitisu B. Zdravilo ImmunoGam je na voljo v vialah 1 ml ali 5 ml in vsebuje 30-70 mg/ml beljakovin iz človeške plazme, od katerih je 96 %
- Subjects who did not show an immune response (no measurable hepatitis B antibodies) after vaccination and for whom a continuous prevention is necessary due to the continuous risk of being infected with
Zdravilo ImmunoGam zagotavlja kratkotrajno zaščito pred virusom hepatitisa B in se uporablja za zdravljenje - nenamerna izpostavitev necepljene osebe (vključno z osebami, katerih cepljenje je nepopolno ali je status - pri bolnikih na hemodializi, dokler cepivo ne postane učinkovito, - pri novorojencih, rojenih prenašalkam virusa hepatitisa B, - pri osebah, ki po cepljenju ne kažejo imunskega odziva (brez merljive količine protiteles proti virusu hepatitisa B), in pri osebah, pri katerih je obvezno stalno preprečevanje zaradi stalnega tveganja okužbe
EXPIRY DATE
Serološke preiskave
CAPSULE, HARD ORAL USE
KAPSULA, TRDA PERORALNO
Pfizer Healthcare Ireland
Pfizer Healthcare Irland
Vancomycin Pfizer Healthcare Ireland
Vancomycin Pfizer Healthcare Irland
DIRECT INTRAVENOUS INJECTION
INTRAVENSKA INJEKCIJA
Vancomycin-Human Teva Gyógyszergyár
VancomycinHuman Teva Gyógyszergyár
POWDER FOR CONCENTRATE FOR
PRAŠEK ZA KONCENTRAT ZA
INJECTION
INJICIRANJE
Hikma Farmacêutica (Portugal), S.A.
Farmacêutica (Portugal), S.A.
ORAL SOLUTION, POWDER FOR INFUSION
ORAL SOLUTION , PRAŠEK ZA RAZTOPINO ZA INFUNDIRANJE
Eli Lilly Italia S.P.A. Vancocina A.P.
Eli Lilly Italy S.P.A.
VANCOMYCIN 500MG POWDER FOR
VANKOMICIN 500 MG PRAŠEK ZA
Hikma Italia S.P.A. Vancomicina
Hikma Italy S.P.A.
VANCOMYCIN HYDROCHLORIDE 128.15MG CAPSULE
VANKOMICINIJEV KLORID128.15MG CAPSULE
VANCOMYCIN 500MG and 1000MG
VANKOMICIN 500 MG IN 1000 MG
VANCOMYCIN HYDROCHLORIDE 1025.2MG UNITS
VANKOMICINIJEV KLORID 1025,2 MG ENOTA
Fresenius Kabi Bulgaria Eood ванкомицин каби VANCOMYCIN 1000MG VIAL
Fresenius Kabi Bulgaria Eood ванкомицин каби VANKOMICIN 1000 MG VIALA
Orion Corporation Vancomycin Orion VANCOMYCIN 500MG VIAL
Orion Corporation Vancomycin Orion VANKOMICIN 500 MG VIALA
Orion Corporation Vancomycin Orion VANCOMYCIN 1000MG VIAL
Orion Corporation Vancomycin Orion VANKOMICIN 1000 MG VIALA
Vanco-Ratiopharm VANCOMYCIN HYDROCHLORIDE
Vanco-Ratiopharm VANKOMICINIJEV PRAŠEK ZA
Vancomycine Teva VANCOMYCIN HYDROCHLORIDE 1G
Vancomycine Teva VANKOMICINIJEV KLORID 1 G
POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION, POWDER FOR ORAL SOLUTION
KONCENTRAT ZA PRIPRAVO RAZTOPINE ZA INFUNDIRANJE ALI PRAŠEK ZA PERORALNO RAZTOPINO
Vancomicina Sala VANCOMYCIN 500MG VIAL
Vancomicina Sala VANKOMICIN 500 MG VIALA
Vancomycin Xellia VANCOMYCIN 125MG CAPSULE
Vancomycin Xellia VANKOMICIN 125 MG KAPSULA
Fresenius Kabi Bulgaria Eood ванкомицин каби VANCOMYCIN 500MG VIAL
Fresenius Kabi Bulgaria Eood ванкомицин каби VANKOMICIN 500 MG VIALA
Bvba
Bv
VANCOMYCIN HYDROCHLORIDE 512.57MG/10 ML
VANKOMICINIJEV KLORID 512,57 MG/10 ML
VANCOMYCIN HYDROCHLORIDE 1025.14MG VIAL
VANKOMICINIJEV KLORID1025.14MG VIAL
Vancomycin Xellia VANCOMYCIN 250MG CAPSULE
Vancomycin Xellia VANKOMICIN 250 MG KAPSULA
POWDER FOR INJECTION
PRAŠEK ZA RAZTOPINO ZA INJICIRANJE
VANCOMYCIN HYDROCHLORIDE 512.57MG VIAL
VANKOMICINIJEV KLORID512.57MG VIAL
VANCOMYCIN HYDROCHLORIDE 500MG/500 MG
VANKOMICINIJEV KLORID 500 MG/500 MG
Vancomycin Xellia VANCOMYCIN 250MG CAPSULE, HARD ORAL USE
Vancomycin Xellia VANKOMICIN 250 MG KAPSULA, TRDA PERORALNO
Vancomycin Actavis VANCOMYCIN 250MG CAPSULE
Vancomycin Actavis VANKOMICIN 250 MG KAPSULA
VANCOMYCIN HYDROCHLORIDE 1G AMPOULE
VANKOMICINIJEV KLORID 1 G AMPULA
Mylan Hospital As Vancomycin Mylan VANCOMYCIN 1000MG VIAL
Mylan Hospital As Vancomycin Mylan VANKOMICIN 1000 MG VIALA
VANCOMYCIN HYDROCHLORIDE 512.571MG UNITS
VANKOMICINIJEV KLORID 512,571 MG ENOTA
Vancomycin Xellia VANCOMYCIN 1000MG VIAL
Vancomycin Xellia VANKOMICIN 1000 MG VIALA
HYDROCHLORIDE 513MG VIAL
KLORID 513 MG VIALA
Mylan Dura Gmbh Vancomycin Mylan VANCOMYCIN 500MG VIAL
Mylan Dura Gmbh Vancomycin Mylan VANKOMICIN 500 MG VIALA
HYDROCHLORIDE 1000MG VIAL
KLORID 1000 MG VIALA
1025.2 - 1040.2MG VIAL
1040,2 MG VIALA
Mylan Dura Gmbh Vancomycin Mylan VANCOMYCIN 1000MG VIAL
Mylan Dura Gmbh Vancomycin Mylan VANKOMICIN 1000 MG VIALA
VANCOMYCIN HYDROCHLORIDE 1025MG/1025 MG
KLORID1025MG/1025 MG
VANCOMYCIN HYDROCHLORIDE 1G BOTTLE
VANKOMICINIJEV KLORID 1 G STEKLENIČKA
POWDER FOR CONCENTRATE FOR SOLUTION FOR
PRAŠEK ZA KONCENTRAT ZA PRIPRAVO RAZTOPINE ZA
Vancomycin Xellia VANCOMYCIN 500MG VIAL
Vancomycin Xellia VANKOMICIN 500 MG VIALA
Vancomycin Actavis VANCOMYCIN 125MG CAPSULE
Vancomycin Actavis VANKOMICIN 125 MG KAPSULA
Mylan Hospital As Vancomycin Mylan VANCOMYCIN 500MG VIAL
Mylan Hospital As Vancomycin Mylan VANKOMICIN 500 MG VIALA
512.5MG VIAL
520,1 MG VIALA
HYDROCHLORIDE 500MG VIAL
KLORID 500 MG VIALA
Vancomycin Vocate VANCOMYCIN 1000MG VIAL
Vancomycin Vocate VANKOMICIN 1000 MG VIALA
VANCOMYCIN HYDROCHLORIDE 0.5G VIAL
Vancomycin Hexal VANKOMICINIJEV KLORID 0,5 G VIALA
Vancomycin Actavis VANCOMYCIN 1000MG VIAL
Vancomycin Actavis VANKOMICIN 1000 MG VIALA
Pharmaceutical Trading Co Ltd
Trading Co Ltd Hydrochloride Pharmaceutical
VANCOMYCIN HYDROCHLORIDE 256MG CAPSULE
VANKOMICINIJEV KLORID256MG CAPSULE